This article provides a detailed guide for researchers and drug development professionals on validating CRISPR off-target effects.
This comprehensive 2024 benchmarking review provides a critical analysis of current methods for detecting off-target effects in genome editing.
This article provides a comprehensive guide for researchers and drug development professionals on evaluating engineered Cas nucleases with altered PAM specificities against the canonical wild-type SpCas9.
This article provides a detailed resource for researchers and drug development professionals on the BLESS (Direct In Situ Breaks Labeling, Enrichment on Streptavidin, and Next-Generation Sequencing) and BLISS (Breaks Labeling...
This article provides a detailed comparison of two premier cytosine base editors, BE4max and Sdd7, tailored for researchers and drug developers.
This comprehensive review details the pivotal role of the BCL11A transcription factor in silencing fetal hemoglobin (HbF) and its emergence as a prime therapeutic target for sickle cell disease (SCD).
This comprehensive guide details the protocol for editing the BCL11A enhancer region to produce exagamglogene autotemcel (exa-cel), an autologous CRISPR-Cas9 edited cell therapy for sickle cell disease and beta-thalassemia.
This article provides a complete framework for implementing amplicon sequencing to assess candidate off-target sites for CRISPR-based therapies.
This article provides a detailed, up-to-date protocol and analysis of the Alt-R HDR Enhancer Protein, a key reagent for enhancing Homology-Directed Repair (HDR) in CRISPR-Cas9 genome editing.
This article explores AiCErec, a cutting-edge AI-assisted platform for recombinase engineering, tailored for researchers and drug development professionals.